Posted On: 03/02/2015 11:09:38 PM
Post# of 30066
HOW FAR does our patent coverage for MANF go?
I might be wrong, however, from my numerous email exchanges with the Commish, he has made it perfectly clear that anyone using recombinant MANF has to go through us - PERIOD! The difference between us having the patent for a specific ailment such as Retinitis Pigmentosa or not such as Roche's biomarkers is control. With Retinitis, we get the whole $$$$, with cancer biomarker, we get some $$$.
Why do you think SAARMA wasn't too pleased of the broad coverage our patent rights had. It doesn't matter whether it is naturally produced in the body or not. We have the "MATTER OF COMPOSITION" patent - BINGO!
P.S. We'll find out soon enough of the "once in a lifetime investment" we are holding soon enough with all the spotlights beginning to shed a flicker of light on us. Once the "SPOTLIGHTS" hits - oh my!
Manolo
I might be wrong, however, from my numerous email exchanges with the Commish, he has made it perfectly clear that anyone using recombinant MANF has to go through us - PERIOD! The difference between us having the patent for a specific ailment such as Retinitis Pigmentosa or not such as Roche's biomarkers is control. With Retinitis, we get the whole $$$$, with cancer biomarker, we get some $$$.
Why do you think SAARMA wasn't too pleased of the broad coverage our patent rights had. It doesn't matter whether it is naturally produced in the body or not. We have the "MATTER OF COMPOSITION" patent - BINGO!
P.S. We'll find out soon enough of the "once in a lifetime investment" we are holding soon enough with all the spotlights beginning to shed a flicker of light on us. Once the "SPOTLIGHTS" hits - oh my!
Manolo
(0)
(0)
